Trial Profile
A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Neflamapimod (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Proof of concept; Therapeutic Use
- Acronyms REVERSE-SD
- Sponsors EIP Pharma
- 06 Oct 2020 According to an EIP Pharma media release, results of this study were reported at the AAT-AD/PD Focus Meeting in April 2020.
- 05 Dec 2019 Results published in EIP Pharma media release .
- 05 Dec 2019 According to an EIP Pharma media release,Professor Philip Scheltens of the VU Medical Center in Amsterdam, Netherlands is a principal investigator of the study.